+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peripheral Neuropathy Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • August 2024
  • Region: Global
  • The Business Research Company
  • ID: 5990968
Peripheral neuropathy is a condition where the peripheral nerves, responsible for transmitting signals between the central nervous system (brain and spinal cord) and the rest of the body, suffer damage or dysfunction. Symptoms typically manifest as numbness, tingling, weakness, and pain, commonly affecting the hands and feet.

The primary types of peripheral neuropathy include chemotherapy-induced, diabetic, HIV/AIDS-associated, and idiopathic. Chemotherapy-induced neuropathy refers to complications resulting from chemotherapy treatment. Diagnosis involves blood tests, biopsies, imaging, and other methods, while treatment options encompass medications, antidepressants, anti-seizure drugs, pain relievers, topical treatments, therapies, nerve stimulation, plasma exchange, physical therapy, and more. End users of these treatments include hospitals, clinics, and ambulatory centers.

The peripheral neuropathy research report is one of a series of new reports that provides peripheral neuropathy market statistics, including the peripheral neuropathy industry's global market size, regional shares, competitors with a peripheral neuropathy market share, detailed peripheral neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral neuropathy industry. This peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral neuropathy market size has grown rapidly in recent years. It will grow from $3.62 billion in 2023 to $4.09 billion in 2024 at a compound annual growth rate (CAGR) of 12.9%. The growth observed in the historic period can be attributed to several factors, the increased prevalence of chronic diseases such as diabetes, heightened awareness regarding the management of neuropathic pain, a growing global geriatric population, expansion of healthcare infrastructure, the establishment of specialized treatment centers, governmental initiatives aimed at enhancing neurological healthcare services, and the rising adoption of innovative treatment options.

The peripheral neuropathy market size is expected to see rapid growth in the next few years. It will grow to $6.66 billion in 2028 at a compound annual growth rate (CAGR) of 13%. Looking forward to the forecast period, growth is expected to continue due to ongoing increases in chronic disease prevalence, notably diabetes and cancer, advancements in pharmacological therapies targeting neuropathic pain pathways, augmented investment in research and development for novel treatment approaches, integration of digital health solutions enabling remote monitoring and personalized management of neuropathic symptoms, a stronger emphasis on patient-centered care models, and improved accessibility to comprehensive healthcare services. Key trends anticipated in the forecast period include the expanding adoption of personalized treatments, the widespread use of wearable devices for real-time monitoring of neuropathic symptoms and treatment responses, the broader availability of telemedicine services for remote consultations and follow-ups, advancements in targeted therapies addressing specific neuropathic pain mechanisms, progress in regenerative medicine techniques, integration of digital therapeutic platforms offering cognitive behavioral therapy and mindfulness-based interventions, and technological advancements in diagnostic tools facilitating early detection and ongoing monitoring of peripheral neuropathy.

The increasing prevalence of diabetes is anticipated to drive the growth of the peripheral neuropathy market in the coming years. Diabetes is a chronic condition characterized by elevated blood glucose levels due to insulin production or usage inefficiencies. The rising prevalence of diabetes is attributed to factors such as rising obesity rates, sedentary lifestyles, and aging populations. Prolonged high blood sugar levels associated with diabetes can lead to peripheral neuropathy, a condition where nerve damage causes symptoms such as pain, tingling, and numbness in the extremities. Effective management of blood sugar levels is critical in preventing or slowing the progression of this complication. For instance, a report from the International Diabetes Federation projected that the number of people living with diabetes could reach 783 million by 2045, up from 643 million in 2030. Thus, the increasing prevalence of diabetes is a key driver of the peripheral neuropathy market.

Leading companies in the peripheral neuropathy market are focusing on developing advanced solutions, including point-of-care devices, to enhance the diagnosis and management of the condition. Point-of-care peripheral neuropathy quantitative screening tests are diagnostic tools used to quickly detect nerve damage, particularly in individuals with diabetes. For example, NeuroMetrix Inc., a US-based medical device manufacturer, introduced the DPNCheck 2 in January 2023. This point-of-care device uses nerve conduction technology to assess peripheral nerve function quantitatively, offering rapid screening for conditions such as diabetic peripheral neuropathy (DPN). It represents a significant advancement over traditional methods such as monofilament and tuning fork tests, providing more efficient and accurate diagnostic capabilities.

Withings, a French connected health technology company, completed the acquisition of Impeto Medical in January 2022, although financial terms were not disclosed. The acquisition encompasses Impeto's proprietary SUDOSCAN technology, renowned for its ability to measure sweat gland responses in the palms and soles. This technology aids in detecting potential nerve damage and monitoring peripheral neuropathies. Impeto Medical, based in France, specializes in manufacturing devices for health status detection, enhancing Withings' portfolio in the health technology sector.

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Asahi Kasei Corporation, Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, ACI Limited, Lexicon Pharmaceuticals, Solasia Pharma KK, Helixmith Co. Ltd., PledPharma AB.

North America was the largest region in the peripheral neuropathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral neuropathy market consists of revenues earned by entities by providing services such as neurological evaluation, pain management, physical therapy, occupational therapy, podiatry services, orthopedic support, nutritional counseling, psychological support, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral neuropathy market also includes sales of pain relief creams, orthopedic shoes, compression socks, tens devices, foot care kits, braces and supports, nutritional supplements, mobility aids, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Peripheral Neuropathy Market Characteristics3. Peripheral Neuropathy Market Trends And Strategies
4. Peripheral Neuropathy Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Peripheral Neuropathy Market Size and Growth
5.1. Global Peripheral Neuropathy Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Peripheral Neuropathy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Peripheral Neuropathy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Peripheral Neuropathy Market Segmentation
6.1. Global Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy-Induced
  • Diabetic
  • Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated
  • Idiopathic
6.2. Global Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Blood Test
  • Biopsy
  • Imaging
  • Other Diagnosis
6.3. Global Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medications
  • Antidepressants
  • Anti-Seizure Medication
  • Pain Reliever
  • Topical Treatment
  • Therapies
  • Nerve Stimulation
  • Plasma Exchange
  • Physical Therapy
  • Other Treatments
6.4. Global Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Centers
7. Peripheral Neuropathy Market Regional And Country Analysis
7.1. Global Peripheral Neuropathy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Peripheral Neuropathy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Peripheral Neuropathy Market
8.1. Asia-Pacific Peripheral Neuropathy Market Overview
(Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Peripheral Neuropathy Market
9.1. China Peripheral Neuropathy Market Overview
9.2. China Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Peripheral Neuropathy Market
10.1. India Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Peripheral Neuropathy Market
11.1. Japan Peripheral Neuropathy Market Overview
11.2. Japan Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Peripheral Neuropathy Market
12.1. Australia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Peripheral Neuropathy Market
13.1. Indonesia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Peripheral Neuropathy Market
14.1. South Korea Peripheral Neuropathy Market Overview
14.2. South Korea Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Peripheral Neuropathy Market
15.1. Western Europe Peripheral Neuropathy Market Overview
15.2. Western Europe Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Peripheral Neuropathy Market
16.1. UK Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Peripheral Neuropathy Market
17.1. Germany Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Peripheral Neuropathy Market
18.1. France Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Peripheral Neuropathy Market
19.1. Italy Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Peripheral Neuropathy Market
20.1. Spain Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Peripheral Neuropathy Market
21.1. Eastern Europe Peripheral Neuropathy Market Overview
21.2. Eastern Europe Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Peripheral Neuropathy Market
22.1. Russia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Peripheral Neuropathy Market
23.1. North America Peripheral Neuropathy Market Overview
23.2. North America Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Peripheral Neuropathy Market
24.1. USA Peripheral Neuropathy Market Overview
24.2. USA Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Peripheral Neuropathy Market
25.1. Canada Peripheral Neuropathy Market Overview
25.2. Canada Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Peripheral Neuropathy Market
26.1. South America Peripheral Neuropathy Market Overview
26.2. South America Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Peripheral Neuropathy Market
27.1. Brazil Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Peripheral Neuropathy Market
28.1. Middle East Peripheral Neuropathy Market Overview
28.2. Middle East Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Peripheral Neuropathy Market
29.1. Africa Peripheral Neuropathy Market Overview
29.2. Africa Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Peripheral Neuropathy Market Competitive Landscape And Company Profiles
30.1. Peripheral Neuropathy Market Competitive Landscape
30.2. Peripheral Neuropathy Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck and Co. Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Novartis AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Bristol Myers Squibb Co
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AstraZeneca Plc
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Peripheral Neuropathy Market Other Major And Innovative Companies
31.1. Abbott Laboratories
31.2. Eli Lilly and Co.
31.3. Asahi Kasei Corporation
31.4. Daiichi Sankyo Co. Ltd.
31.5. Sun Pharmaceutical Industries Ltd
31.6. Aurobindo Pharma
31.7. Cadila Pharmaceuticals Ltd.
31.8. Dr. Reddy's Laboratories
31.9. Cipla Ltd.
31.10. Apotex Inc
31.11. Hikma Pharmaceuticals PLC
31.12. Lupin Limited
31.13. Grunenthal GmbH
31.14. ACI Limited
31.15. Lexicon Pharmaceuticals
32. Global Peripheral Neuropathy Market Competitive Benchmarking33. Global Peripheral Neuropathy Market Competitive Dashboard34. Key Mergers And Acquisitions In The Peripheral Neuropathy Market
35. Peripheral Neuropathy Market Future Outlook and Potential Analysis
35.1 Peripheral Neuropathy Market In 2028 - Countries Offering Most New Opportunities
35.2 Peripheral Neuropathy Market In 2028 - Segments Offering Most New Opportunities
35.3 Peripheral Neuropathy Market In 2028 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

Peripheral Neuropathy Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peripheral neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for peripheral neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peripheral neuropathy market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Chemotherapy-Induced; Diabetic; Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated; Idiopathic
2) By Diagnosis: Blood Test; Biopsy; Imaging; Other Diagnosis
3) By Treatment: Medications; Antidepressants; Anti-Seizure Medication; Pain Reliever; Topical Treatment; Therapies; Nerve Stimulation; Plasma Exchange; Physical Therapy; Other Treatments
4) By End-User: Hospitals; Clinics; Ambulatory Centers

Key Companies Mentioned: Pfizer Inc.; Merck and Co. Inc.; Novartis AG; Bristol Myers Squibb Co; AstraZeneca Plc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Pfizer Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Bristol Myers Squibb Co
  • AstraZeneca Plc
  • Abbott Laboratories
  • Eli Lilly and Co.
  • Asahi Kasei Corporation
  • Daiichi Sankyo Co. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Cadila Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories
  • Cipla Ltd.
  • Apotex Inc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Grunenthal GmbH
  • ACI Limited
  • Lexicon Pharmaceuticals
  • Solasia Pharma KK
  • Helixmith Co. Ltd.
  • PledPharma AB

Methodology

Loading
LOADING...